CY2082B1 - Use of sertindole for the treatment of schizophrenia - Google Patents
Use of sertindole for the treatment of schizophreniaInfo
- Publication number
- CY2082B1 CY2082B1 CY9802082A CY9802082A CY2082B1 CY 2082 B1 CY2082 B1 CY 2082B1 CY 9802082 A CY9802082 A CY 9802082A CY 9802082 A CY9802082 A CY 9802082A CY 2082 B1 CY2082 B1 CY 2082B1
- Authority
- CY
- Cyprus
- Prior art keywords
- sertindole
- schizophrenia
- treatment
- dopamine neurones
- neurones
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB898908085A GB8908085D0 (en) | 1989-04-11 | 1989-04-11 | New therapeutic use |
Publications (1)
Publication Number | Publication Date |
---|---|
CY2082B1 true CY2082B1 (en) | 1998-10-16 |
Family
ID=10654774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY9802082A CY2082B1 (en) | 1989-04-11 | 1998-10-16 | Use of sertindole for the treatment of schizophrenia |
Country Status (18)
Country | Link |
---|---|
US (1) | US5112838A (xx) |
EP (1) | EP0392959B1 (xx) |
JP (1) | JP2775191B2 (xx) |
KR (1) | KR920008703B1 (xx) |
AT (1) | ATE157005T1 (xx) |
AU (1) | AU621735B2 (xx) |
CA (1) | CA2014208C (xx) |
CY (1) | CY2082B1 (xx) |
DE (2) | DE69031290T2 (xx) |
DK (1) | DK0392959T3 (xx) |
GB (1) | GB8908085D0 (xx) |
HK (1) | HK1002825A1 (xx) |
IE (1) | IE81157B1 (xx) |
IL (1) | IL94021A (xx) |
NL (1) | NL980008I1 (xx) |
NZ (2) | NZ243765A (xx) |
SG (1) | SG48234A1 (xx) |
ZA (1) | ZA902785B (xx) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5238945A (en) * | 1989-04-11 | 1993-08-24 | H. Lundbeck A/S | Method of treating psychoses |
DK238190D0 (da) * | 1990-10-03 | 1990-10-03 | Lundbeck & Co As H | Depotderivater |
US5643784A (en) * | 1990-12-04 | 1997-07-01 | H, Lundbeck A/S | Indan derivatives |
NZ243065A (en) * | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
DK206591D0 (da) * | 1991-12-23 | 1991-12-23 | Lundbeck & Co As H | Behandling af psykoser |
DK8492D0 (da) * | 1992-01-23 | 1992-01-23 | Lundbeck & Co As H | Behandling af psykoser |
DK123493D0 (da) * | 1993-11-01 | 1993-11-01 | Lundbeck & Co As H | Compounds |
WO1997035584A1 (en) | 1996-03-25 | 1997-10-02 | Eli Lilly And Company | Method for treating pain |
ZA973433B (en) * | 1996-04-24 | 1997-12-10 | Shionogi & Co | A sertindole-containing preparation and a method for producing the same. |
AU745641B2 (en) * | 1997-10-27 | 2002-03-28 | Cortex Pharmaceuticals, Inc. | Treatment of schizophrenia with ampakines and neuroleptics |
GB9805716D0 (en) * | 1998-03-17 | 1998-05-13 | Merck Sharp & Dohme | Therapeutic agents |
US6489341B1 (en) | 1999-06-02 | 2002-12-03 | Sepracor Inc. | Methods for the treatment of neuroleptic and related disorders using sertindole derivatives |
FR2802101B1 (fr) | 1999-12-10 | 2003-02-28 | Aventis Pharma Sa | Association de cymemazine et d'un neuroleptique atypique |
US20040023951A1 (en) * | 2001-06-18 | 2004-02-05 | Bymaster Franklin Porter | Combination therapy for treatment of psychoses |
ATE503845T1 (de) * | 2001-12-10 | 2011-04-15 | Novartis Pharma Gmbh | Verfahren zur behandlung von psychosen und schizophrenie auf der basis eines polymorphismus im cntf gen |
IL163992A0 (en) * | 2002-03-27 | 2005-12-18 | Lundbeck & Co As H | Method for manufacture of sertindole |
CA2525366A1 (en) * | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines |
GB0326148D0 (en) | 2003-11-10 | 2003-12-17 | Lilly Co Eli | Morpholine derivatives |
CA2567249A1 (en) * | 2004-04-19 | 2006-10-05 | Jds Pharmaceuticals, Llc | Lithium combinations, and uses related thereto |
BRPI0510942A (pt) * | 2004-05-11 | 2007-07-17 | Pfizer Prod Inc | combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b |
MY147767A (en) * | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
AR049646A1 (es) * | 2004-06-16 | 2006-08-23 | Janssen Pharmaceutica Nv | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados |
TW200616608A (en) * | 2004-07-09 | 2006-06-01 | Forest Laboratories | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
MY142329A (en) * | 2004-08-24 | 2010-11-15 | Janssen Pharmaceutica Nv | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents. |
AU2006249577A1 (en) * | 2005-05-20 | 2006-11-30 | Janssen Pharmaceutica N.V. | Process for preparation of sulfamide derivatives |
US20070212412A1 (en) * | 2005-09-08 | 2007-09-13 | H. Lundbeck A/S | Stable solid formulation of sertindole |
US8691867B2 (en) * | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
US8492431B2 (en) * | 2005-12-19 | 2013-07-23 | Janssen Pharmaceutica, N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
US20070155823A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents |
US20070155824A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis |
US8497298B2 (en) * | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
US20070155827A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
US20070191460A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis |
US20070191474A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine |
US20070191450A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder |
US20070191451A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents |
JP2009537635A (ja) * | 2006-05-19 | 2009-10-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 癲癇の処置のための共同−療法 |
TW200821296A (en) * | 2006-06-01 | 2008-05-16 | Lundbeck & Co As H | Use of sertindole for the preventive treatment of suicidal behaviour |
ATE523602T1 (de) | 2006-06-12 | 2011-09-15 | Hadasit Med Res Service | Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen |
JP2010510314A (ja) | 2006-11-22 | 2010-04-02 | シーサイド セラピューティクス,エルエルシー | 精神遅滞、ダウン症候群、脆弱x症候群および自閉症の治療方法 |
WO2008106144A2 (en) * | 2007-02-28 | 2008-09-04 | Nupathe Inc. | Implants for the treatment of psychiatric states |
US20090247617A1 (en) * | 2008-03-26 | 2009-10-01 | Abdel-Magid Ahmed F | Process for the preparation of benzo-fused heteroaryl sulfamates |
WO2009128058A1 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
CA2729056A1 (en) | 2008-06-23 | 2010-01-21 | Janssen Pharmaceutica Nv | Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
EP2321011A1 (en) * | 2008-06-25 | 2011-05-18 | Pfizer Inc. | Diaryl compounds and uses thereof |
US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
US8252801B1 (en) | 2009-06-03 | 2012-08-28 | Abbott Laboratories | Treatment of schizophrenia and related disorders |
CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4359468A (en) * | 1981-02-25 | 1982-11-16 | Boehringer Ingelheim Ltd. | Antiallergic N-[4-(indolyl)-piperidino-alkyl]-benzimidazolones |
IE58370B1 (en) * | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
US4742057A (en) * | 1985-12-05 | 1988-05-03 | Fujisawa Pharmaceutical Co., Ltd. | Antiallergic thiazole compounds |
ZA891901B (en) * | 1988-03-17 | 1989-11-29 | Merrell Dow Pharma | Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy |
-
1989
- 1989-04-11 GB GB898908085A patent/GB8908085D0/en active Pending
-
1990
- 1990-03-21 IE IE105190A patent/IE81157B1/en not_active IP Right Cessation
- 1990-03-30 DE DE69031290T patent/DE69031290T2/de not_active Expired - Lifetime
- 1990-03-30 DE DE1998175011 patent/DE19875011I2/de active Active
- 1990-03-30 AT AT90610022T patent/ATE157005T1/de active
- 1990-03-30 SG SG1996008153A patent/SG48234A1/en unknown
- 1990-03-30 EP EP90610022A patent/EP0392959B1/en not_active Expired - Lifetime
- 1990-03-30 DK DK90610022T patent/DK0392959T3/da active
- 1990-04-03 NZ NZ243765A patent/NZ243765A/en unknown
- 1990-04-03 NZ NZ233179A patent/NZ233179A/en unknown
- 1990-04-05 IL IL9402190A patent/IL94021A/en active Protection Beyond IP Right Term
- 1990-04-06 JP JP2090502A patent/JP2775191B2/ja not_active Expired - Lifetime
- 1990-04-09 CA CA002014208A patent/CA2014208C/en not_active Expired - Lifetime
- 1990-04-10 AU AU53037/90A patent/AU621735B2/en not_active Expired
- 1990-04-11 KR KR1019900004984A patent/KR920008703B1/ko not_active IP Right Cessation
- 1990-04-11 ZA ZA902785A patent/ZA902785B/xx unknown
- 1990-04-11 US US07/508,240 patent/US5112838A/en not_active Expired - Lifetime
-
1998
- 1998-02-18 NL NL980008C patent/NL980008I1/nl unknown
- 1998-02-19 HK HK98101302A patent/HK1002825A1/xx not_active IP Right Cessation
- 1998-10-16 CY CY9802082A patent/CY2082B1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
NZ243765A (en) | 1997-09-22 |
EP0392959A3 (en) | 1992-05-06 |
NZ233179A (en) | 1996-12-20 |
DE19875011I2 (de) | 2004-07-01 |
EP0392959B1 (en) | 1997-08-20 |
DE69031290T2 (de) | 1998-01-02 |
KR920008703B1 (ko) | 1992-10-08 |
AU5303790A (en) | 1990-10-18 |
IE81157B1 (en) | 2000-05-03 |
DK0392959T3 (da) | 1999-03-29 |
SG48234A1 (en) | 1998-04-17 |
IE901051L (en) | 1990-10-11 |
US5112838A (en) | 1992-05-12 |
CA2014208A1 (en) | 1990-10-11 |
DE69031290D1 (de) | 1997-09-25 |
ZA902785B (en) | 1991-06-26 |
JPH02290872A (ja) | 1990-11-30 |
JP2775191B2 (ja) | 1998-07-16 |
ATE157005T1 (de) | 1997-09-15 |
KR900015730A (ko) | 1990-11-10 |
IL94021A0 (xx) | 1991-01-31 |
IL94021A (en) | 1994-01-25 |
AU621735B2 (en) | 1992-03-19 |
CA2014208C (en) | 1996-03-19 |
NL980008I1 (nl) | 1998-05-06 |
HK1002825A1 (en) | 1998-09-18 |
GB8908085D0 (en) | 1989-05-24 |
EP0392959A2 (en) | 1990-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2082B1 (en) | Use of sertindole for the treatment of schizophrenia | |
TR200000129T2 (tr) | Yepyeni spiroazabisiklik heterosiklik bileşikler. | |
DE69225421D1 (de) | Sumatriptan enthaltende Arzneimittel | |
TW376319B (en) | Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine | |
DE69825292D1 (de) | Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen | |
SE8804629D0 (sv) | New therapeutically active compounds | |
NO178338C (no) | Analogifremgangsmåte for fremstilling av en terapeutisk aktiv benzimidazolforbindelse samt mellomprodukt | |
ES2033879T3 (es) | Derivados cetonicos como medicamentos para el tratamiento o prevencion del sindrome de abstinencia. | |
NO167204C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive diacylderivater av 4-(trialkylbenzyl)-piperazinylforbindelser. | |
NO178336C (no) | Analogifremgangsmåte for fremstilling av en terapeutisk aktiv benzimidazolforbindelse og mellomprodukter | |
NO167456C (no) | Analogifremgangsmaate for fremstilling av den terapeutisk aktive forbindelse 7-(3-amino-1-pyrrolidinyl)-8-brom-1-syklopropyl-6-fluor-1,4-dihydro-4-okso-3-quinolinkarboksylsyre | |
AP9901474A0 (en) | Pharmaceutical composition for treating viral diseases. | |
ZA877454B (en) | Therapeutic agent for the treatment of peptic ulcer disease | |
MY133438A (en) | Morpholinobenzamide salts | |
NO984651L (no) | Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet | |
CA2154485A1 (en) | Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders | |
HK1022420A1 (en) | The use of homocysteine derivatives for the treatment of bacterial infections. | |
JO1653B1 (en) | The current benzimidazole is a therapeutically active method for preparing it | |
ES2150400A6 (es) | Una composicion para el tratamiento de desordenes ulcerosos del tracto gastrointestinal. | |
IT8919216A0 (it) | Dispositivo per la cura chirurgica dell'astigmatismo. |